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Negative Control of p53 by Sir2 Promotes
Cell Survival under Stress
and Anderson, 2000). Early studies demonstrated that
CBP/p300, a histone acetyl-transferase (HAT), acts as
a coactivator of p53 and potentiates its transcriptional
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led to the discovery of an FAT (transcriptional factor1150 St. Nicholas Avenue
acetyl-transferase) activity of CBP/p300 on p53; thisNew York, New York 10032
finding also predicted that acetylation may represent a2Department of Biology
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By developing site-specific acetylated p53 antibod-
ies, CBP/p300 mediated acetylation of p53 was further
confirmed in vivo by a number of studies (reviewed inSummary
Appella and Anderson, 2000). Significantly, the steady-
state levels of acetylated p53 are stimulated in responseThe NAD-dependent histone deacetylation of Sir2 con-
to various types of stress, indicating the important rolenects cellular metabolism with gene silencing as well
of p53 acetylation in stress response (reviewed in Ito etas aging in yeast. Here, we show that mammalian Sir2
al., 2001). By introducing a transcriptional defective p53physically interacts with p53 and attenuates p53-medi-
mutant (p53Q25S26) into mice, it was found that the mutantated functions. Nicotinamide (Vitamin B3) inhibits an
mouse thymocytes and ES cells failed in undergoingNAD-dependent p53 deacetylation induced by Sir2,
DNA damage-induced apoptosis (Chao et al., 2000; Ji-and also enhances the p53 acetylation levels in vivo.
menez et al., 2000). Interestingly, this mutant proteinFurthermore, Sir2 represses p53-dependent apopto-
was phosphorylated normally at the N terminus in re-sis in response to DNA damage and oxidative stress,
sponse to DNA damage but could not be acetylated atwhereas expression of a Sir2 point mutant increases
the C terminus (Chao et al., 2000), supporting a criticalthe sensitivity of cells in the stress response. Thus,
role of p53 acetylation in p53-dependent apoptotic re-our findings implicate a p53 regulatory pathway medi-
sponse (Chao et al., 2000; Luo et al., 2000). Furthermore,ated by mammalian Sir2. These results have signifi-
it has been found that oncogenic Ras as well as PMLcant implications regarding an important role for Sir2
can upregulate the levels of acetylated p53 in normalin modulating the sensitivity of cells in p53-dependent
primary fibroblasts, and also induce premature senes-apoptotic response and the possible effect in cancer
cence in a p53-dependent manner (Pearson et al., 2000,therapy.
Ferbeyre et al., 2000). p53 acetylation may also play a
critical role in protein stabilization (Rodriguez et al.,Introduction
2000; Nakamura et al., 2000; Ito et al., 2001). In addition,
another independent study showed that acetylation, butThe p53 tumor suppressor exerts anti-proliferative ef-
not phosphorylation of the p53 C terminus, may be re-fects, including growth arrest, apoptosis, and cell senes-
quired to induce metaphase chromosome fragility in thecence, in response to various types of stress (Levine, 1997;
cell (Yu et al., 2000).
Prives and Hall, 1999; Vogelstein et al., 2000). Mutations
The yeast silent information regulator 2 (Sir2) protein
within the p53 gene have been well documented in more
belongs to a family of histone deacetylases (reviewed
than half of all human tumors. Accumulating evidence in Guarente, 2000; Shore, 2000). Sir2 activity is nicotin-
further indicates that, in the cells that retain wild-type amide adenine dinucleotide (NAD)-dependent, but can
p53, other defects in the p53 pathway also play an im- not be inhibited by TSA (Imai et al., 2000; Landry et al.,
portant role in tumorigenesis (Prives and Hall, 1999). 2000a; Smith et al., 2000). The NAD-dependent deacety-
The molecular function of p53 that is required for tumor lase activity of Sir2 is essential for its functions, and this
suppression involves its ability to act as a transcriptional activity also connects its biological role with cellular
factor in regulating downstream target gene expression metabolism in yeast (Guarente, 2000). Recently, mam-
(reviewed in Nakano and Vousden, 2001; Yu et al., 2001). malian Sir2 homologs have been found to also contain
p53 is a short-lived protein whose activity is main- the NAD-dependent histone deacetylase activity (Imai
tained at low levels in normal cells. Tight regulation of et al., 2000; Smith et al., 2000), further supporting that
p53 is essential for its effect on tumorigenesis as well the enzymatic activity is key to elucidate the molecular
as maintaining normal cell growth. The precise mecha- mechanism for its mediated functions. Among Sir2 and
nism by which p53 is activated by cellular stress is not its homolog proteins (HSTs) in yeast, Sir2 is the only
completely understood; it is generally thought to involve protein exclusively localized in nuclei, whose activity is
mainly posttranslational modifications of p53, including critical for both gene silencing and extension of yeast
phosphorylation and acetylation (reviewed in Appella life span (reviewed in Guarente, 2000). Based on protein
sequence homology analysis, mouse Sir2 and its hu-
man ortholog SIRT1 (or human Sir2) are the closest3 Correspondence: wg8@columbia.edu
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homologs to yeast Sir2 (Imai et al., 2000; Frye, 1999,
2000). Both of them exhibit nuclear localization (S.I. and
L.G. unpublished data; also in Figure 6C), but their bio-
logical functions remain unclear.
Since homologs of Sir2 have been identified in almost
all organisms examined including bacteria, which has
no histone proteins (reviewed in Guarente, 2000; Frye,
1999, 2000), it is likely that Sir2 also targets nonhistone
proteins for functional regulation. Our preliminary results
uncovered an activity in protein fractions from mamma-
lian nuclear extract that could effectively deacetylate
p53 in the presence of TSA. In support of the possibility
that mammalian Sir2 targets p53 for functional regula-
tion, we present evidence that mouse Sir2 as well as
human SIRT1 can directly bind p53 both in vitro and in
vivo, and promotes cell survival under stress by specifi-
cally repressing p53-dependent apoptotic response.
This discovery has important implications for elucidating
a biological role for Sir2 in mammalian cells.
Results
Mammalian Sir2 Interacts with p53 Both
In Vitro and In Vivo
Since mouse Sir2 shares a highly conserved region at
the C terminus with human SIRT1 (Figure 1A), but not
with any other mammalian Sir2 homologs (Frye, 1999,
2000), we developed a polyclonal antibody against the
C terminus (amino acid 480–737) of mouse Sir2. By
Western blot analysis, this antibody can detect both
mouse Sir2 and human SIRT1 proteins, but not other
human Sir2 homologs (J.L. and W.G., unpublished data, Figure 1. Interactions between p53 and Mammalian Sir2 Both In
also see Figures 1B and 1C). Next, we used this antibody Vitro and In Vivo
to investigate whether p53 interacts with Sir2or hSIRT1 (A) Schematic representation of the high homology regions between
mouse Sir2 and human SIRT1 (hSIRT1). The core domain repre-in normal cells. Cell extracts from both human (H460)
sents the very conserved enzymatic domain among all Sir2 familyand mouse cells (F9), which express wild-type p53 pro-
proteins (Frye, 1999, 2000).teins, were immunopreciptated with -Sir2, or with the
(B) The interaction between p53 and hSIRT1 in H460 cells.
preimmune serum. Western blot analysis revealed that (C) The interaction between p53 and Sir2 in F9 cells.
this antibody immunoprecipitated both Sir2 and hSIRT1 (D) The interaction between p53 and hSIRT1 in HCT116 cells either
(lower panels, Figures 1B and 1C). More importantly, both at the normal condition (lanes 1–3) or after DNA damage treatment
by etoposide (lanes 4–6). Western blot analyses of the indicatedhuman and mouse p53 were clearly detected in the
whole cell extract (WCE) (lanes 1, 4), or immunoprecipitates withrespective -Sir2 immunoprecipitations from cell ex-
anti-Sir2 antibody (IP/anti-Sir2) (lanes 2, 5) prepared from different
tracts, but not in the control immunoprecipitations with cell extracts, or control immunoprecipitates with preimmunoserum
the preimmune serum, indicating that p53 interacts with from the same extracts (lanes 3, 6), with anti-p53 monoclonal anti-
mammalian Sir2 in normal cells. Interestingly, this inter- bodies (DO-1 for human p53, 421 for mouse p53), or anti-sir2
antibody.action was strongly detected in the cells after DNA dam-
(E) Direct interactions of Sir2 with GST-p53. The GST-p53 full-age treatment (Figure 1D), suggesting that the possible
length protein (GST-p53) (lane 1), the N terminus of p53 protein (1-73)regulation of p53 by mammalian Sir2may be still effec-
(lane 2), the middle part of p53 (100-290) (lane 3), the C terminus of
tive after DNA damage. p53 (290-393) (lane 4), and GST alone (lane 6) were used in GST
Furthermore, we tested whether Sir2 directly inter- pull-down assay with in vitro translated 35S-labeled full-length mouse
Sir2.acts with p53 in vitro. As shown in Figure 1E, 35S-labeled
in vitro-translated Sir2 strongly bound to immobilized
GST-p53 but not to immobilized GST alone (lane 1 ver-
sus 6). Moreover, Sir2 tightly bound to the C-terminal Deacetylation of p53 by Mammalian Sir2
domain of p53 (GST-p53CT) (lane 4, Figure 1E), also In order to test whether p53 could be specifically deacet-
bound to the central DNA binding domain (GST-p53M), ylated by mammalian Sir2 in vitro, the mouse Sir2
but showed no binding to the N-terminal domain of p53 protein was expressed with the N-terminal Flag epitope
(GST-p53NT) (lane 3 versus 2, Figure 1E). Thus, the in cells and purified to near homogeneity on the M2-
above findings demonstrate that p53 interacts with agarose affinity column (lane 3, Figure 2A). As shown in
Figure 2B, 14C-labeled acetylated p53 was efficientlymammalian Sir2 both in vitro and in vivo.
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To establish the role for mammalian Sir2 in deacety-
lating p53 in cells, we used an acetylated p53-specific
antibody to monitor the steady-state levels of acetylated
p53 in vivo (Luo et al., 2000). As indicated in Figure 2C,
a high level of acetylated p53 was found in the cells
cotransfected with p300 and p53 (lane 1); however, p53
acetylation levels were significantly abolished by ex-
pression of either Sir2 or hSIRT1 (lanes 2, 4). In con-
trast, a point mutation at the highly conserved histidine
residue at the core domain (Sir2-355A and hSIRT1-
363Y) effectively abolished the deacetylase activity (lane
3 versus 2, lane 5 versus 4, Figure 2C). Furthermore,
neither SIRT5, another human Sir2 homolog, nor poly
(ADP-ribose) polymerase (PARP), whose activity is also
NAD-dependent (reviewed in Vaziri et al., 1997), had any
significant effect on p53 acetylation (lanes 6,7, Figure
2C). In addition, in contrast to HDAC-mediated deacety-
lation of p53 (Luo et al., 2000), Sir2 still strongly deacet-
ylated p53 in the presence of TSA (lane 4 versus 3, Figure
2D) even though the steady state level of acetylated p53
was elevated when the cells were treated with TSA (lane
3 versus 1, Figure 2D). Taken together, these data impli-
cate a strong TSA-independent p53 deacetylation activ-
ity of mammalian Sir2.
Inhibition of Sir2-Mediated p53 Deacetylation
by Nicotinamide
To further elucidate the in vivo effect by endogenous
Figure 2. TSA-Insensitive Deacetylation of p53 by Mammalian Sir2 Sir2, we tried to identify an inhibitor for Sir2-mediated
(A) Colloidal blue staining of a SDS-PAGE gel containing protein deacetylase activity on p53. Deacetylation of acetyl-
Marker (lane 1), a control eluate from M2 loaded with untransfected lysine by Sir2 is tightly coupled to NAD hydrolysis,
cell extract (lane 2), and 100 ng of the highly purified Flag-tagged producing nicotinamide and an acetyl-ADP-ribose com-
Sir2 recombinant protein (lane 3).
pound (1-O-acetyl-ADP-ribose) (Landry et al., 2000b;(B) Deacetylation of p53 by Sir2. 2.5 g of 14C-labeled acetylated
Tanner et al., 2000; Tanny and Moazed, 2001). Althoughp53 (lane 1) was incubated with either the control eluate (lane 4),
the purified 10 ng of Sir2 (lanes 2 and 3), or the same amount of the molecular mechanism of Sir2-mediated NAD-depen-
Sir2 in the presence of 500 nM TSA (lane 5) for 60 min at 30C. dent deacetylation needs to be detailed, it was proposed
NAD (50 M) was also added in each reaction except lane 2. The that formation of an enzyme-ADP-ribose intermediate
proteins were analyzed by resolution on SDS-PAGE and autoradiog- through NAD hydrolysis is critical for this chemical reac-
raphy (upper) or Coomassie blue staining (lower).
tion (Landry et al., 2000b). Since nicotinamide is the first(C) Reduction of the steady-state levels of acetylated p53 by both
product from hydrolysis of the pyridinium-N-glycosidicmouse Sir2 and human SIRT1 expression. Western blot analysis
of H1299 cell extracts from the cells cotransfected with p53 and bond of NAD, it may function as an inhibitor for its de-
p300 (lane 1), or in combination with Sir2 (lane 2), or in combination acetylase activity (Landry et al., 2000b). We thus tested
with hSIRT1 (lane 4), or Sir2-355A (lane 3), or hSIRT1-363Y (lane whether nicotinamide is able to inhibit the deacetylase
5), or hSIRT5 (lane 6), or PARP (lane 7) by acetylated p53-specific activity of Sir2 on acetylated p53 in vitro.
antibody (upper) or DO-1 for total p53 (lower). The highly conserved
Similar reactions as described above (Figure 2B), werehistidine residue at the core domain was replaced by alanine for
set up by incubating labeled p53 substrate, recombinantmouse Sir2 (aa 355) (Sir2-355A), or replaced by tyrosine for human
SIRT1 (aa 363) (hSIRT1-363Y). Sir2 and NAD (50 M) alone, or in combination with
(D) Deacetylation of p53 by Sir2 in the presence of TSA. The ace- nicotinamide (5 mM). As shown in Figure 3A, 14C-labeled
tylated p53 levels in the cells cotransfected with p53 and p300 (lanes acetylated p53 was efficiently deacetylated by Sir2
1, 3), or cotransfected with p53, p300 and Sir2 (lanes 2, 4). Cells were (lane 2); however, the deacetylation activity was com-
either not treated (lanes 1,2) or treated with 500 nM TSA (lanes 3, 4).
pletely inhibited in the presence of nicotinamide (lane 3
versus 2). As a negative control, 3-AB (3-aminobenz-
amide), a strong inhibitor of PARP which is involveddeacetylated by purified Sir2 (lane 3), but not by a
control eluate (lane 4). Importantly, NAD is required for in another type of NAD-dependent protein modifications
(Vaziri et al., 1997), showed no significant effect on Sir2-Sir2-mediated deacetylation of p53 (lane 2 versus lane
3, Figure 2B). In addition, the deacetylase inhibitor TSA, mediated deacetylation (lane 4 versus 3, Figure 3A).
Furthermore, we examined the effect of Sir2 expres-which significantly abrogates HDAC1-mediated deacet-
ylase activity on p53 (Luo et al., 2000), had no apparent sion on endogenous levels of acetylated p53. Mouse
embryonic fibroblast (MEF) cells, which express the wild-effect on Sir2-mediated p53 deacetylation (lane 5, Fig-
ure 2B). These results indicate that the Sir2can strongly type of p53, were infected with either a pBabe retrovirus
empty vector or a pBabe retrovirus containing Sir2.deacetylate p53 in vitro, and that this activity depends
on NAD. We first examined the protein levels of p53 activation
Cell
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Figure 3. Abrogation of Mammalian Sir2-
Mediated Deacetylation of p53 by Nicotin-
amide
(A) Sir2-mediated deacetylation of p53 is in-
hibited by nicotinamide. 2.5 g of 14C-labeled
acetylated p53 (lane 1) was incubated with
10 ng of purified Sir2 and 50 M NAD alone
(lane 2), or in the presence of either 5 mM of
nicotinamide (lane 3) or 3 mM of 3-AB
(3-aminobenzamide) (lane 4) for 60 min at
30C. The proteins were analyzed by resolu-
tion on SDS-PAGE and autoradiography (up-
per) or Coomassie blue staining (lower).
(B) Enhancement of endogenous p53 acetyla-
tion levels by nicotinamide. Western blot
analysis of cell extracts from untreated H460
cells (lane 1), or the cells treated with etopo-
side alone (lane 2), or in combination with
nicotinamide (lane 3).
(C) The Sir2-mediated deacetylation of en-
dogenous p53 was abrogated in the presence
of nicotinamide. Cell extracts from the mock-
infected MEF p53/ cells (lanes 1–2, 5–6),
or the pBabe-Sir2 infected cells (lanes 3–4,
7–8), either untreated (lanes 1, 3, 5, 7), or
treated with etoposide and TSA (lanes 2, 4),
or in combination with nicotinamide (lanes 6,
8) for 6 hr were analyzed by Western blot with
acetylated p53-specific antibody (upper) or
DO-1 for total p53 (lower).
(D) Synergistic induction of p53 acetylation
levels by TSA and nicotinamide during DNA
damage response. Western blot analysis of
cell extracts from the H460 cells treated with
etoposide alone (lane 2), or in combination
with TSA (lane 3), or TSA and nicotinamide
(lane 4), or TSA and 3-AB (lane 5) for 6 hr by
acetylated p53-specific antibody (upper) or
DO-1 for total p53 (lower). The cell extracts
from untreated cells (lane 1), or treated with
ALLN (50 M) were also included (lane 6).
in response to DNA damage in these cells by Western Figure 3B, after the wild-type p53-containing human
lung carcinoma cells (H460) were treated by etoposide,blot analysis. Similar protein levels of p53 activation
were induced in both types of cells after etoposide treat- acetylation of p53 was indeed induced (lane 2, versus
1). Significantly, the cellular levels of acetylated p53ment for 6 hr (lanes 3, 4 versus lanes 1, 2, lower panel,
Figure 3C). In the mock-infected cells, as expected, the induced by DNA damage were enhanced when the cells
were treated with nicotinamide (lane 3 versus 2, Figureacetylation level of p53 was significantly enhanced by
DNA damage (lane 2 versus 1, upper panel, Figure 3C). 3B), indicating an inhibitory effect of nicotinamide on
endogenous Sir2-mediated p53 deacetylation.However, the same DNA damage treatment failed to
stimulate the p53 acetylation in the pBabe-Sir2 in- Furthermore, we have previously shown that p53 can
be deacetylated by a PID/MTA2/HDAC1 complex,fected cells even in the presence of TSA (lane 4 versus 2,
upper panel, Figure 3C), indicating that Sir2 expression whose activity is completely abrogated in the presence
of TSA (Luo et al., 2000). Therefore, the enhancement ofresults in deacetylation of endogenous p53. Notably,
this Sir2-mediated effect was completely abrogated the acetylation level of p53 by TSA during DNA damage
response may be due mainly to its inhibitory effect onby nicotinamide treatment (lane 8 versus 6, Figure 3C).
Thus, these data indicate that Sir2-mediated deacety- endogenous HDAC1-mediated deacetylase activity (lane 3
versus 2, Figure 3D). Since no significant p53 acetylationlation of p53 can be inhibited by nicotinamide both in
vitro and in vivo. was detected in the cells treated with a proteasome
inhibitor ALLN (lane 6, Figure 3D), indicating that the
observed stimulation of p53 acetylation is induced byMaximum Induction of p53 Acetylation Levels
in Normal Cells Requires Inhibition DNA damage, not through p53 stabilization. Strikingly,
a super induction of p53 acetylation was evident whenof Endogenous Sir2 Activity
After we found that nicotinamide has a strong inhibitory the cells were treated with both TSA and nicotinamide
(lane 4 versus 3, Figure 3D). In contrast, 3-AB treatmenteffect on Sir2-mediated deacetylation in vivo (Figure
3C), we further tested whether the endogenous Sir2 is had no effect on the level of p53 acetylation (lane 5
versus 3, Figure 3D), indicating that PARP-mediatedcritical in regulating the p53 acetylation levels in normal
cells during the DNA damage response. As indicated in poly-ADP ribosylation has no effect on p53 acetylation.
Negative Control of p53 by Sir2
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Figure 4. Repression of p53-Mediated Tran-
scriptional Activation by Mammalian Sir2
(A) MEF (p53/) cells were transiently trans-
fected with 10 ng of CMV-p53 alone, or in
combination with indicated amount of Sir2
together with the PG13-Luc reporter con-
struct by calcium phosphate precipitation es-
sentially as previously described (Luo et al.,
2000).
(B) Western blot analysis of indicated trans-
fected H1299 cell extracts with anti-p53
(DO-1), anti-p21 (C-19) and anti--actin.
(C and D) MEF (p53/) cells were transiently
transfected with 10 ng of CMV-p53 alone, or
in combination with 5g of either CMV-Sir2,
or CMV-hSIRT1, or CMV-hSIRT5 (C), or CMV-
Sir2-355A as indicated (D) together with the
PG13-Luc reporter construct. All transfec-
tions were done in duplicate and representa-
tive experiments depict the average of three
experiments with standard deviations indi-
cated.
Thus, these data clearly indicate that maximum induc- cifically represses p53-dependent transactivation, and
that this repression requires its deacetylase activity.tion of p53 acetylation requires inhibitors for both types
of deacetylases (HDAC1 and Sir2), and that endoge- To further test the biological role of mammalian Sir2,
we examined its modulation on p53-dependent apopto-nous Sir2 plays an important role in the regulation of
the p53 acetylation levels induced by DNA damage. sis. p53 null cells (H1299) were transfected with p53
alone or cotransfected with p53 and Sir2. The trans-
fected cells were fixed, stained for p53, and analyzed forRepression of p53-Mediated Functions
by Mammalian Sir2 Requires Its apoptotic cells (SubG1) (Luo et al., 2000). As indicated in
Figure 5A, overexpression of p53 alone induced signifi-Deacetylase Activity
To determine the functional consequence of mammalian cant apoptosis (32.3% SubG1). However, cotransfection
of p53 with Sir2 significantly reduced the level of apo-Sir2-mediated deacetylation of p53, we tested its effect
on p53-mediated transcriptional activation. A mamma- ptosis (16.4% SubG1), while the mutant Sir2-355A was
severely impaired in this effect (29.5% SubG1) (Figureslian p53 expression vector (CMV-p53), alone or in combi-
nation with different amounts of mouse Sir2 expression 5A and 5B). Similar results were also obtained by using
the Annexin V assay (see Supplemental Figure S4). Takenvector (CMV-Sir2), was cotransfected into MEF (p53/)
cells along with a reporter construct containing syn- together, these data demonstrate that mammalian Sir2
is involved in the regulation of both p53-mediated tran-thetic p53 binding sites placed upstream of the lucifer-
ase gene (PG13-Luc). As shown in Figure 4A, Sir2 scriptional activation and p53-dependent apoptosis,
and that the deacetylase activity is required for thesestrongly repressed p53-mediated transactivation in a
dose-dependent manner (up to 21-fold), and expression Sir2-mediated effects on p53.
of human SIRT1 showed a similar effect on the p53
target promoter (Figure 4C). Furthermore, an acetyla- The Role of Mammalian Sir2 in Stress-Induced
Apoptotic Responsetion-defective p53 mutant (Luo et al., 2000) was partially
impaired in the Sir2-mediated repression (see Supple- Our data have indicated that mammalian Sir2 can de-
acetylate p53 both in vitro and in vivo (Figure 2); moremental Figures S1 and S2; http://www.cell.com/cgi/
content/full/107/2/137/DC1). Significantly, Sir2 ex- importantly, Sir2 can attenuate p53-mediated tran-
scriptional activation (Figure 4). To elucidate the physio-pression attenuated p53 sequence-specific DNA bind-
ing activity (see Supplemental Figure S3), and also abro- logical significance for this Sir2-mediated regulation,
we examined its effect on DNA damage-induced apo-gated p53-dependent induction of endogenous p21
expression (lane 3 versus 2, Figure 4B). In contrast, ptotic response. For this study, we chose the same MEF
(p53/) cells as described above (Figure 3C), whichneither the Sir2-355A mutant nor SIRT5, both of which
are defective in p53 deacetylation (Figure 2C), had any were infected with either a pBabe retrovirus empty vec-
tor or a pBabe retrovirus containing Sir2. After the DNAeffect on the p53-mediated transactivation (Figures 4C
and 4D). These data suggest that mammalian Sir2 spe- damage treatment by etoposide, the cells were stained
Cell
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Figure 5. Inhibition of p53-Dependent Apo-
ptosis by Sir2
(A and B) H1299 cells were transfected with
p53 alone, or cotransfected with p53 and
Sir2, or cotransfected with p53 and Sir2-
355A. After transfection, the cells were fixed,
stained for p53 by FITC-conjugated -p53 an-
tibody, analyzed for apoptotic cells (subG1)
according to DNA content (PI staining).
(C and D) Mammalian Sir2 has no effect on
the Fas mediated apoptosis. Both mock in-
fected cells and pBabe-Sir2 infected MEF
p53/ cells were either not treated (1 and
2) or treated with 100 ng/ml Fas antibody in
presence of actinomycin D (0.25 g/ml) (3
and 4).
The experiments were repeated more than
three times and the results depict the average
of three experiments with standard devia-
tions indicated (B and C).
with PI and analyzed by flow cytometric analysis for a pBabe retrovirus empty vector or a pBabe retrovirus
containing Sir2. By immunofluorescence staining, weapoptotic cells (SubG1) according to DNA content. As
shown in Figure 6A, the cells mock infected with the found that p53 in these infected cells was induced signif-
icantly after hydrogen peroxide treatment, along withpBabe-vector, were susceptible to etoposide-induced
cell death, with about 48% of the cells apoptotic after Sir2 localized in the nuclei detected by immunostaining
with specific antibodies (Figure 6C). Importantly, Sir2exposure to 20 M of etoposide (3 versus 1, Figure 6A).
In contrast, the pBabe-Sir2 infected MEF (p53/) cells expression significantly promotes cell survival under ox-
idative stress. As indicated in Figure 6D, the cells mockwere more resistant to apoptosis induced by the same
dose of etoposide, with only 16.4% apoptotic cells (4 infected with the pBabe-vector, were susceptible to
H2O2-induced cell death, with more than 80% of the cellsversus 3, Figures 6A and 6B). Since no significant apo-
ptosis was detected in MEF (p53/) cells by the same being killed after 24 hr exposure to 200 M H2O2 (II
versus I). In contrast, the pBabe-Sir2 infected cellstreatment (D.C. and W.G., unpublished data), the in-
duced apoptosis observed in MEF (p53/) cells is totally were much more resistant to death by the same dose
of H2O2, with about 70% of the cells surviving after 24p53-dependent. Thus, these results indicate that Sir2
significantly inhibits p53-dependent apoptosis in re- hr of H2O2 treatment (IV versus III, Figure 6D).
Taken together, these results suggest that mamma-sponse to DNA damage.
Since stimulation of p53 acetylation as well as p53- lian Sir2 promotes cell survival under stress by inhib-
iting p53-dependent apoptosis.dependent apoptosis have also been implicated in many
other types of stress response (reviewed in Ito et al.,
2001), we examined the role of mammalian Sir2 in the Mammalian Sir2 Has No Effect on p53-Independent
Cell Death Induced by Anti-Fasoxidative stress response. Recent studies have indi-
cated that oxidative stress-induced cell death is p53- In order to determine the specificity of mammalian Sir2-
mediated protection of cells from apoptosis, we exam-dependent (Yin et al., 1998; Migliaccio et al., 1999). We
chose early-passage normal human fibroblast (NHF) ined whether Sir2 has any effect on p53-independent,
Fas-mediated apoptosis. The MEF (p53/) cells wereIMR-90 cells for this study since it has been demon-
strated that p53-dependent apoptosis can be strongly infected with either a pBabe retrovirus empty vector or
a pBabe retrovirus containing Sir2. After the treatmentinduced by hydrogen peroxide treatment in these cells
(Chen et al., 2000). IMR-90 cells were infected with either by anti-Fas (100 ng/ml) for 24 hr, the cells were harvested
Negative Control of p53 by Sir2
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Figure 6. Inhibition of the p53-Dependent Apoptosis in Response to Stress by Mammalian Sir2
(A) Repression of the apoptotic response to DNA damage by Sir2. Both mock infected cells and pBabe-Sir2 infected MEF p53/ cells
were either not treated (1 and 2) or treated with 20 M etoposide. The cells were analyzed for apoptotic cells (subG1) according to DNA
content (PI staining). Similar results were obtained for three times, and the representative data depict the average of three experiments with
standard deviations indicated (B). (C) Subcellular localization of p53 and Sir2 in the pBabe-Sir2 infected IMR-90 cells. p53 and Sir2 were
detected with either -p53 (DO-1) (visualized by green fluorescence from secondary antibody staining with anti-mouse IgG-FITC), or affinity
purified -Sir2 antibody (visualized by red fluorescence from secondary antibody staining with anti-rabbit IgG conjugated to Alexa 568). The
cells were counterstained with DAPI to visualize the nuclei as essentially described before (Guo et al., 2000). Cells were either not treated (I)
or treated with 100 M H2O2 (II, III, IV) for 24 hr. (D) Inhibition of the apoptotic response to oxidative stress by mammalian Sir2. Both mock
infected cells and pBabe-Sir2 infected cells were either not treated (I and III) or treated with 200 M H2O2 (II and IV). 24 hr later, the cells
were photographed under a microscope.
and further analyzed for apoptotic cells (SubG1). As ptotic. However, in contrast to the strong protection of
p53-dependent apoptosis by Sir2 during DNA damageshown in Figure 5D, the cells mock infected with the
pBabe vector, were susceptible to anti-Fas induced cell response in the MEF (p53/) cells (Figures 6A and 6B),
Sir2 expression had no significant effect on Fas-medi-death, with about 31.7% of the cells becoming apo-
Cell
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Figure 7. Expression of a Sir2 Point Mutant
(hSIRT1-363Y) Increases the Sensitivity of the
Cells in Response to Stress
(A) The levels of p53 are induced by DNA
damage in both mock infected and pBabe-
hSIRT1-363Y infected cells. Western blot
analysis of the cell extracts from both types
of cells by anti-Sir2 polyclonal antibody (up-
per) or anti-p53 monoclonal antibody (DO-1)
(lower). Cells were either not treated (lanes 1,
2) or treated with 20 M of etoposide (lanes
3, 4) for 6 hr.
(B) Expression of the Sir2 mutant enhances
the acetylated p53 levels induced by DNA
damage. The cell extracts obtained from
treated or untreated cells were first immuno-
precipitated with anti-acetylated p53 anti-
body and the immunoprecipitates were ana-
lyzed by Western blot with -p53 (DO-1).
(C) DNA damage induced expression of p21
and Bax in both mock infected and pBabe-
hSIRT1-363Y infected cells. Both types of
cells were -radiated (3 or 6 Gy); 3 hr later,
the cells were collected for Western blot anal-
ysis for p53, p21, Bax, and -actin.
(D and E) Expression of the Sir2 mutant in-
creases the sensitivity of the cells in stress-
induced apoptotic response. Both mock in-
fected cells and pBabe-hSIRT1-363Y infected
cells were either not treated (I and III) or
treated with 50 M H2O2 (II and IV) (E), or
treated with different concentration of adria-
mycin as indicated; 48 hr later, the cells were
collected for analysis (D).
ated apoptosis in the MEF (p53/) cells (Figures 5C and endogenous Sir2-mediated deacetylation of p53 (lane
5D). Thus, these results further support a specific role for 4 versus 3, Figure 7B). We further tested whether
mammalian Sir2 in regulating p53-mediated apoptosis. hSIRT1-363Y expression has any effect on p53 target
genes induced by DNA damage. As indicated in Figure
7C, both p21 and Bax were induced in the cells after DNAExpression of a Sir2 Point Mutant Increases
damage; interestingly however, the expression levels ofthe Sensitivity of Cells in the Stress Response
both p21 and Bax in hSIRT1-363Y infected cells wereTo further demonstrate that endogenous Sir2 regulates
significantly higher than those in mock-infected cells,endogenous p53 under normal conditions, we intro-
indicated that hSIRT1-363Y expression abrogates theduced a Sir2 point mutant (hSIRT1-363Y), which is
endogenous Sir2-mediated repression on p53-depen-functional-defective in p53 deacetylation (Figure 2C),
dent transactivation. Moreover, although the IMR-90into normal human cells. IMR-90 cells were infected
cells were susceptible to H2O2-induced cell death afterwith either a pBabe retrovirus empty vector or a pBabe
exposure to 200 M H2O2 (Figure 6D), the cells wereretrovirus containing hSIRT1-363Y. As indicated in Fig-
relatively resistant to the treatment with a lower concen-ure 7A, the pBabe-hSIRT1-363Y infected cells ex-
tration of H2O2 (50M) (II versus I, Figure 7E). In contrast,pressed a significant amount of the mutant protein
hSIRT1-363Y expression led to the cells very sensitivewhereas similar levels of p53 were induced in both types
to such a mild treatment (50 M H2O2); less than 30%of cells after DNA damage treatment (lanes 3, 4 versus
of the cells were able to survive after the treatmentlanes 1, 2, Figure 7A). Significantly, the levels of acet-
(IV versus III, Figure 7E). In order to corraborate theseylated p53 were strongly enhanced in the pBabe-
results, we also test whether hSIRT1-363Y expressionhSIRT1-363Y infected cells, indicating that hSIRT1-363Y
functions as a dominant negative mutant and inhibits increases the sensitivity of the cells in DNA damage-
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induced cell death. As shown in Figure 7D, the pBabe- these phosphorylation events contribute to p53 stabili-
zation and activation by preventing the binding withhSIRT1-363Y infected cells are much more sensitive to
DNA damage-induced cell death when the cells were Mdm2 (reviewed in Appella and Anderson, 2000; Shieh
et al., 1997). Mdm2 itself is also phosphorylated by ATMtreated with different concentrations of a DNA damage-
inducing reagent adriamycin. during DNA damage response, and this modification
attenuates its inhibitory potential on p53 (Maya et al.,Taken together, these results suggest that endoge-
nous Sir2 is critically involved in deacetylating p53 2001). Furthermore, while p53 is strongly stabilized and
highly acetylated in stressed cells, acetylation of theas well as regulating p53-mediated biological functions
under physiological conditions. C-terminal multiple lysine sites may occupy the same
sites responsible for Mdm2-mediated ubiquitination
(Rodriguez et al., 2000; Nakamura et al., 2000), and theDiscussion
highly acetylated p53 can not be effectively degraded
by Mdm2 without deacetylation (Ito et al., 2001). Thus,The present data reveal the existence of a p53 regulatory
in contrast to unstressed cells, the main p53 negativepathway that is controlled by mammalian Sir2. Sir2
regulatory pathway mediated by Mdm2 is severelyis involved in gene silencing and extension of life span
blocked at several levels in response to DNA damagein yeast and C. elegans (reviewed in Guarente, 2000;
(Maya et al., 2001). Under these circumstances, theTissenbaun and Guarente, 2001). Although the mamma-
Sir2-mediated regulation may become a major factorlian homolog has also been shown to contain a unique
in controlling p53 activity, making it possible for cellshistone deacetylase activity (Imai et al., 2000; Smith et
to adjust the p53 activity for DNA repair before commit-al., 2000), its biological function remains to be eluci-
ting to apoptosis.dated. We show here (1) that p53 strongly binds to
Interestingly, using a different approach, Vaziri et al.mouse Sir2 as well as its human ortholog hSIRT1 both
(2001 [this issue of Cell]) found that -radiation-inducedin vitro and in vivo, (2) that p53 is a substrate for the
p53-dependent apoptosis is also inhibited by Sir2 ex-NAD-dependent deacetylase of mammalian Sir2, (3)
pression. Thus, our findings together with their resultsthat the Sir2-mediated deacetylation antagonizes p53-
further imply that Sir2 may modulate the sensitivity ofdependent transcriptional activation and apoptosis, (4)
cells in various types of stress response through inhib-that the Sir2-mediated deacetylation of p53 is inhibited
iting p53-mediated function.by nicotinamide both in vitro and in vivo, (5) that Sir2
specifically inhibits p53-dependent apoptosis in re-
sponse to DNA damage as well as oxidative stress, but Attenuation of p53-Mediated Transactivation
not the p53-independent, Fas-mediated cell death, and by Sir2
(6) expression of a Sir2 point mutant increases the Earlier studies indicated that p53-mediated transcrip-
sensitivity of the cells in response to stress. These re- tional activation is sufficient and also absolutely re-
sults are especially relevant to the multiple regulatory quired for its effect on cell growth arrest, while both
pathways of p53 in vivo and, since the acetylation levels transactivation-dependent and -independent pathways
of p53 are stimulated in response to various types of are involved in p53-mediated apoptosis (reviewed in
stress, to the role of mammalian Sir2 in stress re- Prives and Hall, 1999). However, there is now growing
sponse. evidence showing that p53 can effectively induce apo-
ptosis by activating proapoptotic genes in vivo (re-
viewed in Nakano and Vousden, 2001; Yu et al., 2001).The Sir2-Mediated Pathway Is Critical for Cells
Under Stress Thus, tight regulation of p53-mediated transactivation
is critical for its effect on both cell growth and apoptosisOur study implicates an Mdm2-independent, negative
regulatory pathway for p53, which further supports the (Chao et al., 2000; Jimenez et al., 2000).
Recent studies indicate that the intrinsic histoneviews that there are multiple pathways in cells for tight
regulation of p53 function (Prives and Hall, 1999; Appella deacetylase activity of Sir2 is essential for its mediated
functions (reviewed in Gurante, 2000). Reversible acet-and Anderson, 2000). In normal cells, Mdm2 is the major
negative regulator for p53, and Mdm2-mediated repres- ylation was originally identified in histones; however,
accumulating evidence indicates that transcriptionalsion appears sufficient to downregulate p53 activity.
Interestingly, while no obvious effect by Sir2 expres- factors are also functional targets of acetylation (re-
viewed in Sterner and Berger, 2000; Kouzarides, 2000).sion was observed in cells at normal conditions, how-
ever, Sir2 became critical in protecting cells from apo- Thus, the transcriptional attenuation mediated by his-
tone deacetylases may act through the effects on bothptosis when cells were either treated by DNA damage or
under oxidative stress (Figure 6). Therefore, we propose histone and nonhistone transcriptional factors (Sterner
and Berger, 2000). Interestingly, microarray surveys forthat this Sir2-mediated pathway is critical for cell sur-
vival when the p53 negative control mediated by Mdm2 transcriptional effects of Sir2 in yeast revealed that Sir2
appears to repress amino acid biosynthesis genes,is severely attenuated in response to DNA damage or
other types of stress. which are not located at traditional “silenced” loci (Bern-
stein et al., 2000). Thus, in addition to silencing (repres-In this regard, p53 is often found as latent forms and
the levels of p53 protein are very low in unstressed cells, sion) at telomeres, mating type loci and ribosomal DNA
(reviewed in Guarente, 2000; Shore, 2000), Sir2 may alsomainly due to the tight regulation by Mdm2 through
functional inhibition and protein degradation mecha- be targeted to specific endogenous genes for transcrip-
tional regulation in yeast.nisms. However, in response to DNA damage, p53 is
phosphorylated at multiple sites at the N terminus, and The precise mechanism by which mammalian Sir2
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pBabepuro vector. Site-directed mutation was generated in theinhibits p53-mediated functions needs to be further elu-
plasmid pRS305-Sir2 using the Gene Edit system (Promega). Tocidated; however, our results suggest that mammalian
construct the human SIRT1 expression construct, DNA sequencesSir2 inhibits p53-mediated apoptosis through attenua-
corresponding to the full-length hSIRT1 (Frye, 1999) were amplified
tion of the transcriptional activation potential of p53. A by PCR from Marathon-Ready Hela cDNA (Clontech), and initially
speculative model would be that the interaction between subcloned into pcDNA3.1/V5-His-Topo vector (Invitrogen), and then
subcloned with a Flag-tag into a pCIN4 vector for expression (Gup53 and Sir2 leads to deacetylation of p53 and—since
et al., 1999). To prepare the Sir2 antibody that can recognize bothp53 sequence-specific DNA binding can also be acti-
human and mouse Sir2, we made a polyclonal antibody againstvated by other mechanisms such as phosphorylation
the highly conserved C terminus of Sir2. DNA sequences corre-and single-stranded DNA—recruitment of the p53-Sir2
sponding to this region (480-737) were amplified by PCR and sub-
complex to the target promoter; the subsequent tran- cloned into pGEX-2T (Pharmacia). -Sir2 antisera were raised in
scription repression may act both through decreasing rabbits against the purified GST-Sir2(480-737) fusion protein (Co-
vance), and further affinity-purified on both protein-A and antigenp53 transactivation capability and through Sir2-medi-
columns.ated histone deacetylation at the target promoter region.
Our study also predicts that other cellular factors may
In Vitro p53 Deacetylation Assayuse a similar mechanism to recruit Sir2 family proteins
The Flag-tagged Sir2 cells were established and expanded infor TSA-insensitive transcriptional regulation in mamma-
DMEM medium, and cell extracts were prepared essentially as pre-
lian cells. viously described (Luo et al., 2000; Gu et al., 1999). The 14C-labeled
acetylated p53 (2.5 g) was incubated with purified Sir2 (10 ng) at
30C for 1 hr either in the presence of 50 M NAD or as indicated.Implications for Cancer Therapy?
The reactions were performed in a buffer containing 50 mM Tris-Inactivation of p53 functions has been well documented
HCl (pH 9.0), 50mM NaCl, 4 mM MgCl2, 0.5 mM DTT, 0.2 mM PMSF,as a common mechanism for tumorigenesis (Vogelstein
0.02% NP-40, and 5% glycerol. The reactions were resolved onet al., 2000). Many cancer therapy drugs have been de-
SDS-PAGE and analyzed by Coomassie blue staining and autoradi-
signed based on either reactivating p53 functions or ography.
inactivating p53 negative regulators. Since p53 is
strongly activated in response to DNA damage mainly Virus Infection and Stress Response
All MEF cells were maintained in DMEM medium supplemented withthrough attenuation of the Mdm2-mediated negative
10% fetal bovine serum, and the IMR-90 cells were maintained inregulatory pathway (Maya et al., 2001), many DNA dam-
Eagle’s minimal essential medium supplemented with 10% fetalage-inducing drugs such as etoposide are very effective
bovine serum and nonessential amino acids. The virus infection andantitumor drugs in cancer therapy (reviewed in Chresta
selection were essentially as described previously (Ferbeyre et al.,
and Hickman, 1996; Lutzker and Levine, 1996). Based 2000). After one-week selection, the cells were either frozen for
on our results that the maximum induction of p53 acet- stock or immediately used for further analysis. About 500,000 MEF
cells were plated on a 10 cm dish 24 hr before treatment. The cellsylation in normal cells requires both types of deacetylase
were then exposed to etoposide (20 m) for 12 hr. After treatment,inhibitors in addition to DNA damage, there are at least
the cells were washed with PBS and fed with normal medium. An-three different p53 negative regulatory pathways in
other 36 hr later, the cells were stained with PI and analyzed bymammalian cells. Interestingly, inhibitors for HDAC-
flow cytometric analysis for apoptotic cells (SubG1) according to
mediated deacetylases, including sodium butyrate, DNA content. In case of the Fas-mediated apoptosis assay, the cells
TSA, SAHA and others, have been also proposed as were treated with actinomycin D (0.25 g/ml) and Fas antibody (100
ng/ml) as previously described (Di Cristofano et al., 1999). In theantitumor drugs (reviewed in Marks et al., 2001; Butler
case of oxidative stress response, the IMR-90 cells were treatedet al., 2000; Yoshida et al., 1995). Thus, we propose that
with H2O2 (50 to 200 M) for 24 hr.the combining DNA damage drugs, HDAC-mediated
deacetylase inhibitors, and Sir2-mediated deacetylase
Detecting Acetylation Levels of p53 in Cellsinhibitors, may have synergistic effects in cancer ther-
For DNA damage response, about 1 million cells were plated on a
apy for maximally activating p53. 10 cm dish 24 hr before treatment. The cells were then exposed to
The differential roles between HDAC1-dependent and etoposide (20 M) and/or other drugs (0.5 M of TSA, 5 mM of
nicotinamide, and 50 M of ALLN) as indicated for 6 hr. After treat-Sir2-mediated regulation on p53 need to be further
ment, the cells were harvested for Western blot analysis. In the caseelucidated; however, in contrast to PID/HDAC1-medi-
of cotransfection assays testing for p53 acetylation levels, H1299ated p53 regulation (Luo et al., 2000), our results have
cells were transfected with 5 g of CMV-p53 plasmid DNA, 5 g ofshown that mammalian Sir2-mediated effect on p53 is
CMV-p300 plasmid DNA, and 10 g of pcDNA3-Sir2 plasmid DNA
NAD-dependent, indicating that this type of regulation as indicated. 24 hr after the transfection, the cells were lysed in a
is closely linked to cellular metabolism (reviewed in Gua- Flag-lysis buffer (50 mM Tris, 137 mM NaCl, 10 mM NaF, 1 mM
EDTA, 1% Triton X-100 and 0.2% Sarkosyl, 1 mM DTT, 10% glycerol,rente 2000; Campisi, 2000). In fact, null mutants of NPT1,
pH 7.8) with fresh proteinase inhibitors, 10 M TSA and 5 mM nico-a gene that functions in NAD synthesis, show pheno-
tinamide (Sigma). The cell extracts were resolved by either 8% ortypes similar to that of Sir2 mutants in silencing (Smith
4%–20% SDS-PAGE gels (Novex) and analyzed by Western blotet al., 2000) and in life extension in response to caloric
with -p53(Ac)-C and -p53(DO-1).
restriction in yeast (Lin et al., 2000). Thus, metabolic rate
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